Article
An update on PARP inhibitors for the treatment of cancer
1 Feb 2015
Abstract excerpt
The development of poly (adenosine diphosphate [ADP]) ribose polymerase (PARP) inhibitors (PARPi) has progressed greatly over the last few years and has shown encouraging results in the BRCA1/2 mutation-related cancers. This article attempts to summarize the rationale and theory behind PARPi, the clinical trials already reported, as well as ongoing studies designed to determine the role of PARPi in patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
